This week’s guest blog post comes to use from David Handelsman, Life Sciences Business Solutions Manager at SAS. You can read more about David here.
As most anyone who’s been in the pharma business, or follows the pharma business knows, the industry is struggling. These struggles span pipelines, revenue, safety, litigation and reputation, among other areas. I’m reminded of the conversation I had with a pharma exec where she was lamenting how far pharma’s reputation had fallen. The industry was being lumped in with guns and tobacco, and its reputation was a far cry from earlier times when pharma was one of the good guys. The really troubling thing for me is that that conversation was 5 years ago. Since then, the only thing that’s really changed is that pharma is now mentioned in the same breath as guns and oil, rather than guns and tobacco.
How do we get out of this hole?
This week’s guest blog post comes to use from David Handelsman, Life Sciences Business Solutions Manager at SAS. You can read more about David here.
As most anyone who’s been in the pharma business, or follows the pharma business knows, the industry is struggling. These struggles span pipelines, revenue, safety, litigation and reputation, among other areas. I’m reminded of the conversation I had with a pharma exec where she was lamenting how far pharma’s reputation had fallen. The industry was being lumped in with guns and tobacco, and its reputation was a far cry from earlier times when pharma was one of the good guys. The really troubling thing for me is that that conversation was 5 years ago. Since then, the only thing that’s really changed is that pharma is now mentioned in the same breath as guns and oil, rather than guns and tobacco.
How do we get out of this hole?
